Medical Device Patents in Nepal: Protecting Hardware Where Drug Patents Don't Reach
The medical device patent Nepal route: mechanisms qualify under Section 2(a) today, unlike pharma products — filing, fees, and the technical committee.
Nepal's pharmaceutical patent story is defined by what it defers: as an LDC, the country has historically not granted pharmaceutical product patents, with the transition clock running toward TRIPS compliance. Medical devices sit in a different story entirely — a nebuliser, a diagnostic assay kit's reader, a prosthetic fitting is a mechanical or electronic invention, and Nepal's patent system protects those today.
That asymmetry makes the medical device patent the strongest IP instrument available in Nepalese medtech. This guide walks the filing, the examination and the money.
In short
A medical device patent in Nepal protects the device's mechanism and working method under Section 2(a) of the PDTA — new processes, methods of manufacture or operation — filed on Schedule 1(a) with a full disclosure and drawings. Examination runs through a technical committee; fees are NPR 1,000 at application and NPR 7,000 at registration in current practice; and the term is 7 years from registration, renewable twice for a 21-year maximum, with annual maintenance inside each renewal term. The device's shape takes a design registration, its brand a trademark, its software copyright.
Why a medical device patent in Nepal is the stronger route today
The pharma asymmetry frames the opportunity. Pharmaceutical product patents are effectively absent under Nepal's LDC-era position, with the transition running toward full TRIPS compliance on the LDC graduation timetable. Devices carry no such deferral: Section 2(a) of the PDTA defines protectable inventions functionally — a method or process, a method of operation or transmission, an invention based on a new theory or formula — and a device's mechanism fits that definition directly.
The practical consequence: a Nepalese medtech innovator can obtain a real patent on the hardware and method today, in the same register where a composition-of-matter claim for a drug would not currently land. Build the portfolio where the system actually protects.
The three protectable layers of a device
Layering is not abundance; it is precision. The patent covers how it works, the design how it looks, the trademark how it is recognised, the copyright the code. Most device disputes in practice implicate two layers at once — the copied device that also copies the label — and the layered portfolio is what gives the response options.
| Device feature | Right | Notes |
|---|---|---|
| Mechanism / working method | Patent (Schedule 1(a)) | Section 2(a) process and method subject matter |
| Outer shape or housing | Industrial design | 5 years renewable twice — 15-year ceiling |
| Brand on the device and packaging | Trademark | Class by class; 7-year renewable term |
| Embedded software | Copyright (+ secrecy where strategic) | Automatic on creation; assignments from developers |
What the DOI expects in the application
The disclosure standard decides outcomes. A description that withholds the operative mechanism risks refusal — or grants a patent that is vulnerable to challenge later. The first document is the one that counts; matter added during examination cannot cure a thin original filing.
- Inventor details: name, address and occupation, as the Act requires
- Full disclosure: the process or method by which the device works, described so a person in the field could reproduce it
- Drawings and maps: where the subject matter needs them — most device filings do
- Assignment basis: where the applicant is not the inventor, the documents establishing the right
- Notarised POA and translation: for foreign filers, through a local agent, with Nepali translation of foreign documents
Examination by technical committee
Nepal's examination is distinctive: the Department of Industry constitutes a technical committee — experts drawn from government technical bodies and institutions such as NAST and RECAST — to examine the application's documents against the disclosure. Findings are communicated to the applicant, who may amend the documents and face re-examination before the decision forms. Responding within the stated period matters; a delayed response is one of the quietest ways to lose a year.
Accepted patents publish in the Nepal Gazette, with objections lying within 35 days of publication, before registration completes the grant.
Fees, term and maintenance arithmetic
The term runs 7 years from registration, renewable at most twice — a hard 21-year ceiling. Each renewal is due within 35 days of expiry with a six-month grace period behind it; beyond grace, cancellation is automatic and the published specification makes refiling impossible. Annual maintenance turns the patent into a year-by-year maintain-or-lapse decision, timed against whether the device is being made, sold or licensed.
| Stage | Cost |
|---|---|
| Application (Schedule 1(a)) | NPR 1,000 |
| Registration at grant | NPR 7,000 |
| Maintenance, years 7–14 | NPR 5,000 per year |
| Maintenance, years 14–21 | NPR 7,500 per year |
| Late renewal (grace period) | Annual fee + NPR 1,000 fine |
Positioning before the transition era
The LDC graduation clock that eventually brings pharmaceutical product patents to Nepal does not change device strategy — devices are protected now — but it changes the market: originator pharma portfolios, device-drug combinations and enforcement standards all arrive with the compliance era. Device innovators who file their hardware positions now, keep the renewals current and document use will hold the kind of granted, maintained patents that the coming framework builds upon. The window to be early is now.
Want this handled for your brand?
IP Watch monitors new trademark publications in Nepal and alerts you to potentially conflicting marks — with the context needed to review them.
This article is general information, not legal advice.